PHASE 1 2017 – 2018

Initiation: Literature Review

O Conduct global scientific scan of patient reported outcomes literature.
O Develop database of patient organizations.

PHASE 2 2019 – 2020

Development: Qualitative

O Qualitative Data:
  O Identify issues associated with the patients’ diseases.
  O Develop new methodology (called GR/P) to collect impact areas.
  O Gather primary data from patients via focus groups and interviews.
  O Analyze and collate data.
  O Conduct Delphi process to validate and affirm the data.

PHASE 3 2020 – 2021

Acquisition & Data Reporting: Quantitative

O Quantitative Data:
  O Develop new patient impact measurement tool (called PRIDD patient impact).
  O Acquire global patient impact data using PRIDD patient impact measurement tool.
  O Further test validity of PRIDD patient impact measurement tool.

PHASE 4 2021

Activation: Data Gathering

O Analyze data using psychometric testing.
O Launch PRIDD patient impact measurement tool globally.
O Report scale development and peer review processes.

PHASE 5 2022+

Application

O Disseminate GRIDD patient impact data.
O Publish articles and reports.
O Educate stakeholders and public.
O Deliver advocacy campaigns.
O Offer patient organizations’ leaders training and support.

OBJECTIVES

O 12,927 scientific articles reviewed.
O Patient impact dataset created.
O 36 dermatology-specific patient-reported measures identified.
O No measure met Cosmin Category A criteria (i.e. none met gold standard).

O GRID dataset enriched and data gaps filled via two rounds of primary impact interviews with patients that represent all continents.
O Poster sessions and paper(s) published on GRID research.

O Pilot and test PRIDD – gold standard patient impact measurement tool.
O Poster sessions and paper(s) published on PRIDD research.

O Final version of PRIDD patient impact measurement tool developed and launched globally.
O Poster sessions and paper(s) published on PRIDD research.

OUTCOMES

O Open source data to:
  • Produce publications and reports.
  • Support advocacy.
  • Improve public policy.
  • Validate patients’ voices.
O Poster sessions and paper(s) published on GRID research.

O Disseminate GRIDD patient impact data.
O Publish articles and reports.
O Educate stakeholders and public.
O Deliver advocacy campaigns.
O Offer patient organizations’ leaders training and support.

PHASE 1: Initiation - Literature Review

2017-18

PHASE 2: Development - Qualitative

2019-20

PHASE 3: Acquisition & Data Reporting - Quantitative

2020-21

PHASE 4: Activation - Data Gathering

2021-22

PHASE 5: Application - Inform, Support, and Advocate

2022+

BENEFITS of GRIDD

PATIENT ORGANIZATIONS

O Access to dataset from PRIDD - World’s first dermatology patient impact measurement tool.
O Evidence to support their missions and fundraising.
O Training, resources to support their work and in turn their patients.
O Patients’ voice integrated in future decision-making.

DATA & EVIDENCE

O Gap in patient-driven research now filled which will:
  • Support publications and reports.
  • Advance research employing the PRIDD patient impact measurement tool.
  • Inform better public health policy.

ADVOCACY & COMMUNICATIONS

O Provide support for GlobalSkin member campaigns to advance their priorities.
O Educate via a global campaign customized by disease and by country (i.e. language).
O Facilitate informed advocacy at local, regional and country levels to improve diagnosis, care and access to treatments.

GLOBAL DERMATOLOGY

O Advocate via a global campaign to advance dermatology.
O Build a collaborative global network of dermatology stakeholders working towards the shared objectives of better care and treatment for patients.
O Elevate the Disability Adjusted Life Years (DALY) ranking for dermatology (used by the WHO for setting global health priorities).